| Literature DB >> 33786201 |
Byeong H Oh1,2, Hyeong C Moon1,3, Aryun Kim4, Hyeon J Kim2, Chae J Cheong5, Young Seok Park1,2,3,6.
Abstract
BACKGROUND: The pathology of Parkinson's disease leads to morphological changes in brain structure. Currently, the progressive changes in gray matter volume that occur with time and are specific to patients with Parkinson's disease, compared to healthy controls, remain unclear. High-tesla magnetic resonance imaging might be useful in differentiating neurological disorders by brain cortical changes.Entities:
Keywords: 7-tesla magnetic resonance imaging; Parkinson’s disease; atrophy; cortex; subcortex
Year: 2021 PMID: 33786201 PMCID: PMC7958639 DOI: 10.1177/2058460120988097
Source DB: PubMed Journal: Acta Radiol Open
Fig. 1.Representative MRI images taken using 7-T MRI. (a) Brain structures from the medial aspect view, (b) anterior aspect view, and (c) coronal view of patients with PD in images taken with 7-T MRI and processed with N3 algorithms. The gray matter (GM) thickness of patients with PD was calculated using these algorithms.
Demographic and clinical characteristics of Parkinson’s disease (PD) patients and healthy controls (HCs).
| Parkinson’s disease ( | Healthy controls ( | ||
|---|---|---|---|
| Age (years)a | 64.50 ± 10.53 | 57.92 ± 13.10 | 0.19 |
| Sex (males/females)b | 3/9 | 2/10 | 1.00 |
| Disease duration (year) | 3.42 ± 1.68 | ||
| MDS-UPDRSIIIc | 28.33 ± 14.56 | ||
| H–Y | 2.38 ± 0.48 |
MDS-UPDRS: Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating scale; H–Y: Hoehn and Yahr scale.
Age was compared using an independent t test.
Sex was assessed using Fisher’s exact test.
P < 0.05.
Note: UPDRS was measured during the “on” state regarding PD medication.
Demographic and clinical characteristics of Parkinson’s disease patients with and without axial symptoms.
| PD with axial Sx. ( | PD without Axial Sx. ( | ||
|---|---|---|---|
| Age (years)a | 66.00 ± 10.42 | 63.43 ± 11.30 | 1.00 |
| Sex (males/females)b | 4/1 | 5/2 | 1.00 |
| Disease duration (year) | 4.40 ± 1.14 | 2.71 ± 1.70 | 0.11 |
| MDS-UPDRSIIIc | 35.20 ± 19.11 | 23.43 ± 8.85 | 0.27 |
| H–Y | 2.60 ± 0.22 | 2.21 ± 0.57 | 0.27 |
MDS-UPDRS: Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating scale; H–Y: Hoehn and Yahr scale.
Age, duration, and the MDS-UPDRS III and H–Y scales were compared using the Mann-Whitney U test.
Sex was assessed using Fisher’s exact test.
P < 0.05.
Note: UPDRS was measured during the “on” state regarding PD medication.
Comparison of cortical volume, cortical thickness, and subcortical volume between the PD and HC groups.
Parkinson’s disease ( | Healthy controls ( | |||||
|---|---|---|---|---|---|---|
| Left hemi | Right hemi | Left hemi | Right hemi | Left hemi | Right hemi | |
| Comparison of cortical volume between the PD and HC groups | ||||||
| Fusiform | 5529.17 | 5820.75 | 6817.08 | 6114.92 | *0.034 | NS |
| Inferior parietal | 10,132.25 | 11,011 | 11,417.58 | 13,497.42 | NS | *0.023 |
| Medial orbitofrontal | 3591.58 | 3325.67 | 3788 | 3605.58 | NS | *0.049 |
| Rostral anterior cingulate | 2744.25 | 1707.25 | 2927 | 1985.08 | NS | *0.046 |
| Rostral middle frontal | 8694.33 | 8892.33 | 10,198.83 | 9685.67 | *0.047 | NS |
| Superior frontal | 19,067.33 | 22,063.58 | 21,613.92 | 23,243.42 | *0.028 | NS |
| Comparison of cortical thickness between the PD and HC groups | ||||||
| Fusiform | 2.11025 | 2.22325 | 2.24717 | 2.24958 | *0.049 | NS |
| Parahippocampal | 2.24175 | 2.11825 | 2.24608 | 2.29317 | NS | *0.018 |
| Comparison of subcortical volume between the PD and HC groups | ||||||
| Cerebellum-white-matter | 7082.28 | 5829.66 | 9892.57 | 8338.94 | NS | *0.045 |
| Cerebellum-cortex | 21,729.63 | 22,506.33 | 27,758.12 | 29,117.14 | *0.013 | **0.004 |
| Hippocampus | 3210.77 | 2549.78 | 3327.99 | 3513.46 | NS | **0.005 |
| Amygdala | 1152.23 | 1076.71 | 1274.57 | 1462.43 | NS | *0.021 |
NS: not significant; PD: Parkinson’s disease; HC: healthy control.
Notes: The PD and HC groups were compared using the independent t test, and nonparametric data analysis was performed using the Mann–Whitney U test. The thresholds of significance were as follows: *P < 0.05, *P < 0.01, and **P < 0.001.
Fig. 2.Comparison of GM volume between PD patients and controls, (a) to (f); comparison of GM thickness between PD patients and controls, (g) and (h); comparison of subcortical volume between PD patients and controls, (i) to (m); comparison of GM volume between PD patients with and without axial symptoms, (n); and comparison of subcortical volume between PD patients with and without axial symptoms, (o).
Lt.: left; HC: healthy control; PD: Parkinson’s disease; Rt.: right.